Company Number: 13887237

Analysis Date: 2025-07-20 16:48 UTC

1. Credit Opinion: APPROVE with conditions
   MR PHARMA CONSULTANCY SERVICES LIMITED is a recently incorporated private limited company operating in the healthcare consultancy sector. Its financials show a positive net current asset position and net assets at £131,930 as of the last reported year. The company is small-scale with minimal liabilities and no audit requirement, indicating a simple financial structure. However, due to its short trading history (just over one year) and limited operating scale (one employee), credit approval should be conditional on monitoring future trading performance and cash flow stability.

2. Financial Strength:
   The balance sheet as at 28 February 2023 shows total current assets of £193,437, comprising £110,577 cash and £82,860 debtors. Current liabilities stand at £61,507, resulting in net current assets of £131,930 and net assets of the same amount. Shareholder funds are strong relative to company size, with virtually no debt beyond short-term liabilities. The company’s financial position appears sound for its scale, with no indication of over-leverage or solvency issues. However, the minimal share capital (£1) and absence of long-term assets are typical for a startup in this sector.

3. Cash Flow Assessment:
   Cash of £110,577 represents a robust liquidity buffer relative to current liabilities of £61,507, indicating good short-term liquidity. Debtors of £82,860 suggest timely revenue generation and collection, though these should be monitored for aging to avoid cash flow risk. Net current assets of £131,930 provide a comfortable working capital position. Given the company has only one employee and low overheads, cash flow coverage for operational costs and short-term obligations appears adequate at this stage.

4. Monitoring Points:

• Track future accounts filings to assess revenue growth, profitability, and cash flow trends over time.
• Monitor debtor aging and collection efficiency to maintain liquidity.
• Watch for any increases in liabilities or cash burn rates that could strain working capital.
• Observe director changes or alterations in ownership/control that may impact governance or financial strategy.
• Verify timely filing of statutory returns to avoid regulatory risks.